QBiotics Group Limited

Based in Australia, QBiotics Group Limited focuses on discovering and developing innovative small molecules for serious medical conditions, specifically in oncology and wound healing. Founded in 2004 in Australia, QBiotics Group Limited specializes in pharmaceutical development. The company recently raised USD 50 mn in March 2021 from TDM Growth Partners, marking its first funding round. Victoria Gordon serves as CEO, guiding the company through its clinical endeavors.

QBiotics specializes in the discovery and development of innovative small molecules aimed at addressing serious medical conditions, particularly in oncology and wound healing. Their core offerings include tigilanol tiglate, an intratumoural oncolytic small molecule undergoing clinical Phase II trials for soft tissue sarcomas (STS) and head and neck cancers, with FDA Orphan Drug Designation granted for STS treatment. Additionally, QBiotics is developing EBC-1013, a wound healing drug candidate poised to enter clinical Phase I trials for venous leg ulcers. The company's research leverages phenotypic screening methodologies, targeting both chronic and acute wounds, as well as antibiotic discovery focusing on bacterial virulence.

QBiotics operates primarily in Australia, with implications for broader markets including North America and Europe, where there is significant demand for advanced therapeutic solutions in oncology and wound care. In the most recent financial year of 2024, QBiotics reported a revenue of USD 1,284,777, with an EBITDA of USD -18,626,238. The company's revenue generation is primarily through collaborations and clinical trials that support the development of its pharmaceutical products, with future revenue streams expected from licensing agreements for its flagship products upon commercialization. In March 2021, QBiotics Group Limited raised USD 50 mn in venture funding from TDM Growth Partners, which will be utilized for product research and development, market expansion, and strengthening its team.

Future initiatives include advancing the clinical trials of tigilanol tiglate and EBC-1013, with an emphasis on expanding into North America and Europe to meet the growing demand for innovative oncology and wound healing therapies.